Pipeline
Dati, scienza e tecnologia che diventano terapia

Silthera sviluppa programmi focalizzati su malattie genetiche rare e ultra-rare, con particolare attenzione alle mutazioni autosomiche dominanti, dove il bisogno clinico è elevato e la precisione progettuale è un fattore decisivo.
Silthera develops programs focused on rare and ultra-rare genetic diseases, with a specific emphasis on autosomal dominant mutations, where clinical need is high and design precision is a decisive factor
Fasi di sviluppo dei profarmaci
Silthera-001
Disease Area: Visceral myopathy type 1
Target: Mutated gene associated with smooth muscle dysfunction
Discovery
Preclinical Research
Regulatory Preclinical
Clinical
Status: Regulatory Preclinical
Technology: siRNA
Silthera-002
Disease Area: Visceral myopathy type 2
Target: Mutated gene associated with smooth muscle dysfunction
Discovery
Preclinical Research
Regulatory Preclinical
Clinical
Status: Preclinical Research
Technology: siRNA
Silthera-003
Disease Area: Osteogenesis imperfecta
Target: Genetic bone disorders
Discovery
Preclinical Research
Regulatory Preclinical
Clinical
Status: Preclinical Research
Technology: siRNA
Silthera-004
Disease Area: Undisclosed
Discovery
Preclinical Research
Regulatory Preclinical
Clinical
Status: Discovery
Technology: siRNA

